Ifosfamide in thymic neoplasms.
The role of systemic chemotherapy and optimal regimen in thymic neoplasms remains uncertain, because they are rare mediastinal tumors, frequently encapsulated or noninvasive at the time of presentation and surgical excision is adequate treatment. Chemotherapy is an essential treatment modality in advanced or recurrent disease and an increased number of publications on this aspect of management has appeared in the last 10 years. Both single-agent and combination chemotherapy have demonstrated activity in the adjuvant and neoadjuvant settings. There are little data concerning the activity of ifosfamide in thymoma and further investigation of the role of this drug in combination chemotherapy regimens, particularly as an alternative to the inclusion of cyclophosphamide, is warranted.
Daniele
O
O
Ospedale Immacolata Concezione, U.O. Oncologia-Azienda-ULSS n. 14, Piove di Sacco, Italy. odaniele@asl14chioggia.veneto.it
Fornasiero
A
A
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use*; D013945:Thymoma / Q000188:drug therapy; D013953:Thymus Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D007069:Ifosfamide